CONCORD, Mass., Aug. 23, 2023 /PRNewswire/ — Comanche Biopharma Corp. today announced that they have received Fast Track designation from the U.S. Food and Drug Administration (FDA) for the investigation of Comanche’s asset CBP-4888 as a novel siRNA therapy for preeclampsia. Preeclampsia…